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Staphylococcus aureus (MRSA) as the most common organism
to cause healthcare-associated infections in the United States.
Incidence of C. difﬁcile infection (CDI) has also increased in
Canada, Europe, and other parts of the world. CDI is associated
with increased lengths of hospital stay, medical costs, morbidity,
and mortality (attributable mortality rate of 6.9% at 30 days
after diagnosis and 16.7% at 1 year) among hospitalized patients.
Nearly every antibiotic along with gastric acid suppression has
been associated with CDI. Among these, cephalosporins, ampi-
cillin, and clindamycin remain important predisposing agents.
Fluoroquinolones, previously infrequently associated with CDI,
have been found to be one of the primary predisposing an-
timicrobials in recent studies. A positive result of a test for
toxigenic C. difﬁcile and/or its toxins in a patient with diarrhea
is considered to be diagnostic for CDI. Most reports of increases
in the incidence and severity of CDI have been associated with
the BI/NAP1/027 strain of C. difﬁcile. This strain produces more
toxins A and B in vitro than do many other strains of C. difﬁcile,
produces binary toxin, and is highly resistant to ﬂuoroquinolones.
Metronidazole and vancomycin remain the primary options for
the treatment of CDI. Several studies suggest that rates of re-
sponse to treatment of CDI with metronidazole are declining and
statistically superior rates of response to vancomycin treatment
for severe disease with metronidazole treatment. Two antimicro-
bials (nitazoxanide and rifaximin) available in the United States
have been used successfully for CDI treatment but lack United
States Food and Drug Administration approval for this indication.
Experimental treatments currently in clinical development in-
clude a toxin-binding polymer (tolevamer), two poorly absorbed
antimicrobials (OPT-80 [diﬁmicin] and ramoplanin), monoclonal
antibodies, and a C. difﬁcile vaccine. General strategies to
prevent and reduce the risk of CDI include adherence of antimi-
crobial usage restriction and stewardship guidelines, preventing
the patient from being exposed to C. difﬁcile (disinfection and
barrier precautions), and meticulous hand hygiene, and probable
implement of probiotics.
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Streptococcus suis is a Gram-positive coccus, causing menin-
gitis, septicaemia, pneumonia, and purulent arthritisis in pigs.
Human infection is acquired through exposure to colonized pigs
or contaminated pig meat. Infection is likely to occur through
direct contact, e.g. through skin lesions during butchering, but
other routes of infection, such as gastro-intestinal, cannot be
excluded. In the past few years the number of reported S. suis
infections in humans has increased signiﬁcantly, with most cases
originating in Southeast Asia where there exists a high density
of pig farming. Increased awareness, improved diagnostics and
the occurrence of outbreaks have contributed to this increase.
Meningitis and sepsis are the most common clinical manifestation
of human S. suis infection. In Vietnam, S. suis is the most com-
mon cause of acute bacterial meningitis in adults. Infections in
children are extremely rare. Meningitis is frequently complicated
by sensineural hearing loss. Adjuvant treatment with dexam-
ethasone is associated with protection against the hearing loss
in S. suis meningitis. S. suis is sensitive to penicillin, although in
very rare cases penicillin resistance has been reported, but high
rates of resistance to tetracycline and erythromycine have been
reported from human and pig isolates worldwide.
Human infections are almost always caused by S. suis serotype 2
(determined by the capsule polysaccharide), whilst infection in
pigs is caused by a number of the 35 known serotypes. Molecular
typing suggests that a very limited number of clones is respon-
sible for human infection. Whole genome sequencing of S. suis
serotype 2 strains indicates that strains of the same clonal com-
plex are highly related and that variation predominantly occurs
through horizontal transfer of mobile genetic elements.
Increased awareness from both clinicians and microbiologists is
needed to fully appreciate the importance of S. suis as a human
pathogen.
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Group A streptococci (GAS) are one of the most common human
pathogens that cause both invasive and noninvasive infections.
GAS associated diseases are more common in children than adults
and clinical presentation ranges from pharyngitis and impetigo
to invasive infections particularly acute rheumatic fever and
acute glomerulonephritis. The M protein is an important viru-
lence determinant in GAS which is determined by the emm gene.
Currently, more than 170 emm types and 750 emm subtypes of
group A streptococci have been described. Studies of GAS emm
typing distribution performed worldwide, have shown a differing
distribution of emm types in different countries and regions SAgs
are thought to contribute to the pathogenesis of severe GAS
infections by virtue of their potent immunostimulatory activ-
ity and the distribution of proﬁles of genes encoding SAgs has
been used as an additional epidemiological tool to explore the
genomic heterogeneity and possible correlation between toxin
gene content and disease type. Since the late 1990s, resistance
to macrolides has been increasingly detected in S. pyogenes in
several European countries and other parts of the world such as
Korea. There are two primary phenotypes of macrolide resistance
in S. pyogenes: the M phenotype mediated by the mef genes and
the MLSB phenotype mediated by the ermB genes. The latter
phenotype can be constitutive, generally mediated by the ermB
gene, or inducible, generally mediated by the ermA subclass TR
(ermA) gene. Many studies have presented evidence that the
phenotypes and R genes of S. pyogenes have changed over time.
We analyzed the emm type and detected the susceptibilities of
antibiotics to these strains and their phenotype of macrolide
resistance. We also investigated the virulence factors including
the superantigens of the strains. Here, we will report that there
were high resistance rates against macrolides in GAS isolates
collected from Chinese pharyngitis and scarlet fever patients
and that the R-gene was mainly the ermB gene. We also found
that the pattern of the emm-type distribution of GAS strains
from Chinese pediatric patients changed with time and there is a
change in the antimicrobial susceptibility and distribution of the
R-gene in a large collection of S. pyogenes clinical isolates from
pediatric patients during the periods 1993 to 1994 and 2005 to
2008, and to establish its association with the emm-type shift.
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Most of the vanA type VRE in China were E. faecium. The re-
sistance rates of the vanA type vancomycin reisitant entericocci
isolates to erythromycin, levoﬂoxacin, ampicillin and rifampin
were 96.7%, 91.7%, 88.3% and 80.8%. All VRE isolates were
susceptible to linezolid. Multilocus sequence typing (MLST) iden-
tiﬁed most of the VRE isolates belonged to clonal complexes
CC17. Vancomycin resistance of vanA type E. faecium isolates
was transferred at a frequency of 7.0 ×10-1 to 2.3×10-7 between
E. faecium strains during ﬁlter mating. Two of the plasmids,
pZB18 (67 kbp) and pZB22 (200 kbp), were highly conjugative
and were able to transfer at high frequencies of around 10-4 and
